Abstract
Coenzyme Q10 (CoQ10) is an endogenous, lipid-soluble electron carrier. In the inner mitochondrial membrane it accepts and donates electrons within oxidative phosphorylation; in its reduced state it can also interrupt lipid-radical propagation. Those functions are foundational biochemistry, but they do not make every clinical claim equally strong.
The most consequential standalone trial, Q-SYMBIO, used 300 mg/day as an adjunct in 420 people with moderate-to-severe chronic heart failure. Its short-term functional and biomarker endpoints were null, while the two-year composite cardiovascular endpoint and several secondary outcomes favored CoQ10. KiSel-10 is not an independent replication of that result: it tested 200 mg/day CoQ10 with 200 micrograms/day selenium in older Swedish adults and cannot identify which component, or the combination, produced the outcome. Geroprotect Essentials I contains 150 mg of CoQ10 and no selenium, vitamins or minerals. No trial has validated the current formula, its proposed cofactor relationships or a human longevity effect.
01 · The molecule
A mobile electron carrier, not a generic “energy molecule”
Crane and colleagues isolated a quinone from beef-heart mitochondria in 1957.1 The molecule now called CoQ10 contains a redox-active benzoquinone head and a long ten-unit isoprenoid tail. The tail keeps it in lipid membranes; the head cycles among oxidized, semiquinone and reduced states.
Within the inner mitochondrial membrane, the CoQ pool accepts electrons from respiratory complex I, complex II and several other dehydrogenases, then delivers them to complex III. This helps establish the proton gradient used to make ATP. That role is essential, but “essential to normal physiology” is not the same as “more is always better.” The clinical question is whether a particular oral preparation changes a meaningful outcome in a defined population.
A frequently repeated aging claim also needs precision. A classic cross-sectional tissue study measured ubiquinone across human organs and found peaks around early life or young adulthood followed by lower tissue concentrations with age.2 It did not demonstrate that declining synthesis causes aging, that every tissue follows one trajectory, or that supplementation reverses biological age.
02 · Exposure
Ubiquinone, ubiquinol and the delivery system
Ubiquinone and ubiquinol are interconverted in the body. The practical absorption question cannot be answered by oxidation state alone because crystal dispersion, carrier lipids, solubilisation, excipients, meal conditions and the person all influence exposure. In a double-blind crossover study, 14 healthy adults received seven 100 mg formulations separated by washouts. Plasma area-under-the-curve values differed substantially; the best-performing products included both an oil-dispersed ubiquinone softgel and a ubiquinol softgel.3
Another crossover study in 21 adults aged 65–74 found that a water-soluble ubiquinone preparation produced 2.4-fold the exposure of its standard ubiquinone comparator, while the 1.7-fold estimate for ubiquinol did not reach statistical significance. Regardless of the consumed form, circulating CoQ10 appeared predominantly as ubiquinol.4 These small, often product-linked studies do not declare one universal winner. They show why a clinical study’s material cannot be matched to a tablet by milligrams alone.
03 · Q-SYMBIO
The strongest standalone outcome trial—at twice the labelled amount, in heart failure
Q-SYMBIO randomized 420 people with moderate-to-severe chronic heart failure to 100 mg of CoQ10 three times daily or placebo, added to standard therapy, for two years. The prespecified short-term endpoints at 16 weeks—NYHA class, six-minute walking distance and NT-proBNP—did not differ significantly. That null phase matters because it prevents a simple story of rapid functional improvement.
At two years, the primary long-term composite of major adverse cardiovascular events occurred in 15% of the CoQ10 group and 26% of placebo (hazard ratio 0.50; 95% CI 0.32–0.80). Cardiovascular mortality, all-cause mortality and heart-failure hospital stays were lower as secondary outcomes, and NYHA class favored CoQ10.5 This is clinically meaningful evidence for adjunctive use in the studied disease population.
The published paper states that Q-SYMBIO received partial support from the International Coenzyme Q10 Association, Pharma Nord and Kaneka. The authors reported no relationships relevant to the paper. Funding does not negate a randomized result, but the named material and commercial support belong in the transfer and replication record.
It is not a healthy-aging trial. It used 300 mg/day, twice the 150 mg in Essentials I, and it did not test a 13-ingredient tablet. Its event findings do not establish that 150 mg improves survival, prevents heart failure or extends life in healthy customers. Nor can the negative 16-week endpoints be erased because later endpoints were positive.
04 · KiSel-10
A valuable combination trial that cannot isolate CoQ10
KiSel-10 randomized 443 community-living Swedish adults aged 70–88 to 200 mg/day CoQ10 plus 200 micrograms/day selenium yeast, or matching placebos, for four years. At a median 5.2 years of follow-up, cardiovascular mortality was 5.9% with the combination and 12.6% with placebo; NT-proBNP and an echocardiographic cardiac-function score also favored active treatment.6
The paper reports that part of the analysis costs was supported by grants from Pharma Nord, the County Council of Östergötland, Linköping University and the Swedish Research Council; Pharma Nord also donated the selenium tablets and CoQ10 capsules. The authors reported no conflicts of interest. This material and funding context is relevant without deciding the result on its behalf.
The study is relevant to the combination it tested. It had no CoQ10-only arm, no selenium-only arm and no factorial design, so it cannot identify whether benefit came from CoQ10, selenium, their interaction or another feature of the trial. Long-term follow-ups and biomarker substudies remain analyses of the same original randomized combination—not new independent CoQ10 trials.
This distinction is especially important for Geroprotect: Essentials I does not list selenium. KiSel-10 therefore cannot validate the current product, and its selenium-dependent biochemical interpretations cannot be marketed as a built-in formula feature.
05 · Other human outcomes
Small average signals, heterogeneous populations and nulls worth keeping
A 12-week double-blind trial provides a useful dose match: 50 people with type 2 diabetes were randomized to 150 mg/day CoQ10 or placebo, and 40 completed the study. Fasting glucose and HbA1c favored CoQ10, but insulin and HOMA-IR did not. Triglycerides and HDL cholesterol decreased while LDL cholesterol increased in the active group, leading the authors to describe glycaemic improvement without a favorable lipid effect.7 Exact numerical dose matching does not overcome the small sample, attrition, disease population or formulation differences.
A 2025 meta-analysis of 45 randomized trials estimated a small average reduction in systolic blood pressure of 3.44 mmHg, with no significant pooled effect on diastolic pressure or heart rate.8 Pooling increases precision, but the trials varied in health status, preparation, amount and duration. The result supports a modest research signal, not a treatment or individual-response promise.
Fatigue evidence illustrates the same tension. A 13-trial meta-analysis reported a modest average improvement across heterogeneous healthy and clinical groups.9 Yet a 236-person randomized trial in women receiving treatment for early breast cancer found that 300 mg/day CoQ10 raised plasma levels but did not improve fatigue, quality of life or depression over 24 weeks.10 A useful synthesis preserves both the pooled direction and the large null rather than promising universal “cellular energy.”
The source review catalogued fertility, migraine, statin symptoms, inflammation, liver enzymes, exercise recovery, skin and other endpoints. Those literatures use different populations, formulations and outcome hierarchies, and many rely on small trials or meta-analyses with variable quality. They are not converted here into a universal benefits list. A focused evidence page is more reliable than presenting every nominally positive biomarker as a proven effect of one product.
06 · FSP1 and ferroptosis
A major mechanistic discovery, not a 150 mg human outcome
Two independent 2019 studies identified FSP1 as a ferroptosis-defense system operating alongside GPX4. FSP1 uses NAD(P)H to reduce CoQ10 to ubiquinol at membranes; ubiquinol can trap lipid peroxyl radicals and slow the chain reaction that drives ferroptosis.1112 This substantially expanded understanding of CoQ biology.
The studies used genetic screens, biochemical systems and cancer-cell models. They did not test oral CoQ10, Geroprotect, aging rate or a healthy human endpoint. The fact that FSP1 uses NAD(P)H also does not prove that supplemental NMN or NR increases FSP1 activity, improves CoQ10 recycling or synergises with oral CoQ10 in people. Metabolic adjacency is a formulation hypothesis until a component-controlled experiment tests the combination.
07 · Formula and safety context
What 150 mg in Essentials I means—and which cofactor story was removed
A full six-tablet labelled serving of Geroprotect Essentials I contains 150 mg of Coenzyme Q10. That matches the nominal amount in one small diabetes trial, but not its population, material or finished-product context. It is half the amount used in Q-SYMBIO and lower than the CoQ10 component in KiSel-10. Cross-study numbers provide orientation; they do not establish equivalent exposure or outcome.
The source memorandum described a “companion cofactor layer” containing selenium, riboflavin, magnesium, iron, betaine, methylfolate, methyl-B12, vitamin C, vitamin E, lipoic acid, carnitine and other micronutrients. None of those ingredients appears in the current 13-active Essentials I formula, and selenium appears in neither bottle. That entire product claim is therefore excluded. Essentials I does contain NMN and several mitochondrial-research ingredients, while Essentials II contains NR, but no controlled study has demonstrated clinical synergy with CoQ10.
CoQ10 is generally well tolerated; mild digestive upset or insomnia can occur. The US National Center for Complementary and Integrative Health identifies potential interactions with warfarin and insulin and possible incompatibility with some cancer treatments.13 This is standard medicine-context guidance, not evidence that 150 mg is unusually hazardous. The current formula has not undergone a dedicated clinical safety or efficacy trial.
Evidence verdict
Foundational biology, meaningful disease-specific evidence and no shortcut to formula validation
| Statement | Evidence boundary |
|---|---|
| CoQ10 carries electrons in mitochondrial respiration | Established biochemistry; it does not by itself predict a supplement outcome. |
| CoQ10 improved long-term outcomes in Q-SYMBIO | Supported at 300 mg/day as adjunctive therapy in moderate-to-severe chronic heart failure; short-term endpoints were null. |
| KiSel-10 independently validates CoQ10 | No. It tested CoQ10 plus selenium without single-component arms. |
| 150 mg improves metabolic health | One small diabetes RCT found mixed results; healthy consumers and the finished formula were not tested. |
| FSP1 proves synergy with NAD precursors | No. The mechanistic pathway has not been tested as a supplement combination in people. |
| Essentials I supplies the memo’s vitamins, minerals and selenium | No. Those ingredients are not part of the current formula and were removed from the product narrative. |
| Essentials I is clinically validated | Unproven. Ingredient and combination-trial evidence are not trials of the finished formula. |
Questions
Frequently asked questions
What does CoQ10 do?
CoQ10 transfers electrons within cellular membranes, including the mitochondrial respiratory chain. In its reduced ubiquinol state it can also interrupt lipid-peroxidation chain reactions.
Is ubiquinol always better than ubiquinone?
No universal rule is supported. Small crossover studies show that oxidation state, carrier lipids, solubilisation and the person all affect exposure. Well-formulated products of either form can outperform a poorly formulated comparator.
Did two independent CoQ10 trials reduce mortality?
Q-SYMBIO tested CoQ10 alone as an adjunct in heart failure. KiSel-10 tested CoQ10 together with selenium in older adults and cannot isolate the CoQ10 contribution. They are not two independent validations of the same intervention.
Does the 150 mg Geroprotect amount match Q-SYMBIO?
No. Q-SYMBIO used 300 mg/day in people with moderate-to-severe chronic heart failure. Essentials I lists 150 mg in a multi-ingredient formula, and exposure equivalence has not been established.
Does Essentials I contain selenium, B vitamins or minerals to “activate” CoQ10?
No. Those ingredients appeared in the source memorandum but are not in the current Essentials I or Essentials II formula. The reviewed article removes that outdated cofactor claim.
Does CoQ10 synergise with NMN or NR?
That has not been demonstrated in a component-controlled human study. A shared pathway or NAD(P)H-dependent mechanism supplies a hypothesis, not clinical synergy evidence.
What product documentation is still needed?
The current batch needs linkage to a certificate that identifies CoQ10 form and assay, plus delivery-matrix and excipient details, relevant contaminants, stability, and finished-product dissolution or another justified exposure-relevant measure.
Primary and authoritative sources
References
- Crane FL, Hatefi Y, Lester RL, Widmer C. Isolation of a quinone from beef heart mitochondria. Biochimica et Biophysica Acta. 1957;25:220–221. DOI 10.1016/0006-3002(57)90457-2.
- Kalén A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tissues. Lipids. 1989;24:579–584. DOI 10.1007/BF02535072.
- López-Lluch G, et al. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutrition. 2019;57:133–140. DOI 10.1016/j.nut.2018.05.020.
- Žmitek K, et al. Comparative bioavailability of different coenzyme Q10 formulations in healthy elderly individuals. Nutrients. 2020;12:784. DOI 10.3390/nu12030784.
- Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO. JACC: Heart Failure. 2014;2:641–649. DOI 10.1016/j.jchf.2014.06.008; PMID 25282031.
- Alehagen U, et al. Cardiovascular mortality and NT-proBNP reduced after combined selenium and coenzyme Q10 supplementation. International Journal of Cardiology. 2013;167:1860–1866. DOI 10.1016/j.ijcard.2012.04.156; PMID 22626835; trial NCT01443780.
- Zahedi H, et al. Effects of CoQ10 supplementation on lipid profiles and glycemic control in patients with type 2 diabetes. Journal of Diabetes & Metabolic Disorders. 2014;13:81. DOI 10.1186/s40200-014-0081-6.
- Karimi M, et al. Effects of coenzyme Q10 administration on blood pressure and heart rate in adults: a systematic review and meta-analysis of randomized controlled trials. International Journal of Cardiology Cardiovascular Risk and Prevention. 2025;26:200424. DOI 10.1016/j.ijcrp.2025.200424.
- Tsai IC, et al. Effectiveness of coenzyme Q10 supplementation for reducing fatigue: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology. 2022;13:883251. DOI 10.3389/fphar.2022.883251.
- Lesser GJ, et al. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. Journal of Supportive Oncology. 2013;11:31–42. PMID 22682875.
- Bersuker K, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688–692. DOI 10.1038/s41586-019-1705-2.
- Doll S, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693–698. DOI 10.1038/s41586-019-1707-0.
- US National Center for Complementary and Integrative Health. Coenzyme Q10: usefulness and safety. Updated authoritative consumer summary; accessed 14 July 2026.










